Next 10 |
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market – ...
2024-05-31 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm...
2024-05-10 16:15:47 ET More on Rallybio Rallybio shares gain on investment from J&J for rare fetal condition treatment Seeking Alpha’s Quant Rating on Rallybio Read the full article on Seeking Alpha For further details see: Rallybio files to se...
2024-05-10 15:00:11 ET More on the markets SPY: Growing Signs The Market Is Overbought SPY: The Shrinking Market For U.S. Companies SPY: Stronger Than Ever For the second consecutive week, investors purchase ETFs and conventional funds Earnings estima...
2024-05-09 12:31:26 ET More on Rallybio Rallybio shares gain on investment from J&J for rare fetal condition treatment Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read ...
- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides Runway into Mid-2026 - Rallybio Corporation (Nasdaq: RLYB), a...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will partici...
2024-04-29 10:10:00 ET April 29, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cannabis, Green, eSport and Tech sectors. This week's new companies are involved in...
- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women - - Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology compan...
2024-04-15 10:00:31 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...
News, Short Squeeze, Breakout and More Instantly...
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market – ...
- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides Runway into Mid-2026 - Rallybio Corporation (Nasdaq: RLYB), a...